Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0000875320-26-000116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-26 | 2026-02-25 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | S - Sale | $487.65 | -4,910 | 20.0K | -20% | -$2.39M |
| 2026-02-26 | 2026-02-24 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $485.11 | -873 | 22.5K | -4% | -$423.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-25 | S | D | 2,410 | $489.00 | 17,559 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-25 | S | D | 2,500 | $486.35 | 19,969 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-24 | F | D | 873 | $485.11 | 22,469 | D | — | — |